An effective vaccine against colon cancer in mice: Use of recombinant adenovirus interleukin-12 transduced dendritic cells

Figure 3 Vaccination with CT26 TP AdVIL-12/DCs enhances anti-tumor immunity in therapeutic tumor models. CT26 tumor cells (5 × 10⁵ cells per mouse) were implanted s.c. in the midflank of naïve BALB/c mice. On d 3 and 10, tumor-bearing mice were injected with 1 × 10⁶ DCs vaccination with CT26 TP AdVIL-12/DCs. As control, tumor bearing mice were treated in parallel with CT26 TP DCs, unstimulated DCs, CT26 tumor lysate alone, or PBS alone. Tumor growth was assessed by calipers every 2-3 d thereafter. Tumor volume was estimated by the formula 4/3 πr³. Statistical analysis used the paired Student’s t test. Data are given as mean ± SE (n = 10 mice in each group). ^aP < 0.05, CT26 TP AdVIL-12/DCs vs CT26 TP DCs or the other control groups (d 19).